Immunology and the elusive AIDS vaccine

Nature

Volumn 464, Issue 7286, 2010, Pages 224-231

  Virgin, Herbert W ^a   Walker, Bruce D ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RAPAMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNOASSAY; VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; DENDRITIC CELL; EVOLUTION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOREGULATION; MUCOSA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE ACTIVATION; VACCINATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANIMALS; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HIV; HIV ANTIBODIES; HUMANS; MUCOUS MEMBRANE;

HARNESS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77949384495     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature08898     Document Type: Review

References (103)

1. Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209-2220 (2009).
2. Buchbinder, S. P. et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881-1893 (2008).
3. McElrath, M. J. et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372, 1894-1905 (2008).
4. Gilbert, P. B. et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis. 191, 666-677 (2005).
5. 1 T-cell responses containing replication of the primary virus. Nature 420, 434-439 (2002).
6. Haase, A. T. Targeting early infection to prevent HIV-1 mucosal transmission. Nature doi:10.1038/nature08757 (this issue).
7. Liu, J. et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457, 87-91 (2009).
8. Wilson, N. A. et al. Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J. Virol. 83, 6508-6521 (2009).
9. Hansen, S. G. et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nature Med. 15, 293-299 (2009).
10. Persistent effector memory CD4 and CD8 T-cell responses were induced in monkeys by CMV vectors expressing SIV Gag, Rev-Tat-Nef and Env, and after repeated low-dose intrarectal challenge with SIV, 4 out of 12 immunized monkeys were protected from systemic spread of infection.
11. Cohen, M. S., Hellmann, N., Levy, J. A., DeCock, K. & Lange, J. The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J. Clin. Invest. 118, 1244-1254 (2008).
12. Kroner, B. L., Rosenberg, P. S., Aledort, L. M., Alvord, W. G. & Goedert, J. J. HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study. J. Acquir. Immune Defic. Syndr. 7, 279-286 (1994).
13. Fowke, K. R. et al. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 348, 1347-1351 (1996).
14. Salazar-Gonzalez, J. F. et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J. Exp. Med. 206, 1273-1289 (2009).
15. Deeks, S. G. & Walker, B. D. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27, 406-416 (2007).
16. 1 T cell help distinguishes HIV-2 from HIV-1 infection. J. Immunol. 176, 6973-6981 (2006).
17. Sodora, D. L. et al. Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts. Nature Med. 15, 861-865 (2009).
18. Martin, M. P. et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nature Genet. 39, 733-740 (2007).
19. 1 T-cell help. Nature 462, 510-513 (2009). In a murine HSV-2 infection model, it is shown that CD4 T-helper cells control migration of CD8 T cells to the mucosa through secretion of IFN-c and induction of local secretion of chemokines.
20. 1 T cells. Nature 417, 95-98 (2002).
21. 1 T cells dictates the level of viremia in naturally SIV-infected sooty mangabeys. J. Clin. Invest. 118, 2039-2049 (2008).
22. 1 T cells in controlling retrovirus replication and spread in persistently infected mice. J. Virol. 72, 6559-6564 (1998).
23. Virgin, H. W., Wherry, E. J. & Ahmed, R. Redefining chronic viral infection. Cell 138, 30-50 (2009).
24. 1 cytotoxic T-cell responses during chronic viral-infection. J. Virol. 68, 8056-8063 (1994).
25. 1 T-cell response determines the outcome of acute friend virus infection. J. Virol. 83 11211-11222 (2009).
26. 1 lymphocyte depletion but does not account for accelerated SIV pathogenesis. J. Exp. Med. 206, 1575-1588 (2009).
27. Scheid, J. F. et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458, 636-640 (2009).
28. Hübner, W. et al. Quantitative 3D video microscopy of HIV transfer across T cell virological synapses. Science 323, 1743-1747 (2009).
29. Walker, L. M. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009). Using a high-throughput screening method, two potent and broadly cross-reactive neutralizing antibodies were isolated that target a novel broadly neutralizing epitope expressed on trimeric envelope protein and spanning conserved regions of variable loops of the gp120 subunit.
30. Derdeyn, C. A. et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303, 2019-2022 (2004).
31. Chen, L. et al. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326, 1123-1127 (2009).
32. Hessell, A. J. et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nature Med. 15, 951-954 (2009).
33. Hessell, A. J. et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5, e1000433 (2009).
34. Johnson, P. R. et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nature Med. 15, 901-906 (2009).
35. Nelson, S. et al. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog. 4, e1000060 (2008).
36. Kwong, P. D. & Wilson, I. A. HIV-1 and influenza antibodies: seeing antigens in new ways. Nature Immunol. 10, 573-578 (2009).
37. Hessell, A. J. et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101-104 (2007).
38. Messer, R. J., Dittmer, U., Peterson, K. E. & Hasenkrug, K. J. Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection. Proc. Natl Acad. Sci. USA 101, 12260-12265 (2004).
39. Tyler, K. L., Mann, M. A., Fields, B. N. & Virgin, H. W. Protective anti-reovirus monoclonal antibodies and their effects on viral pathogenesis. J. Virol. 67, 3446-3453 (1993).
40. Mehlhop, E. et al. Complement activation is required for induction of a protective antibody response against West Nile virus infection. J.Virol.79, 7466-7477 (2005).
41. McClellan, K. B., Gangappa, S., Speck, S. H. & Virgin, H. W. Antibody-independent control of gamma-herpesvirus latency via B cell induction of anti-viral T cell responses. PLoS Pathog. 2, e58 (2006).
42. Hasenkrug, K. J., Brooks, D. M. & Chesebro, B. Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness. Proc. Natl Acad. Sci. USA 92, 10492-10495 (1995).
43. 1 T-cell responses to different HIV proteins have discordant associations with viral load. Nature Med. 13, 46-53 (2007).
44. 1 T cells suppress simian immunodeficiency virus replication. J. Virol. 81, 1517-1523 (2007).
45. Chen, H. et al. Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes. J. Virol. 83, 3138-3149 (2009).
46. Day, C. L. et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350-354 (2006).
47. 1 T cell survival in HIV infection. J. Exp. Med. 203, 2281-2292 (2006).
48. 1 T cells leads to reversible immune dysfunction. Nature Med. 12, 1198-1202 (2006).
49. 1 T cells correlates with disease progression and defines a reversible immune dysfunction. Nature Immunol. 8, 1246-1254 (2007).
50. Querec, T. D. et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nature Immunol. 10, 116-125 (2009).
51. Moir, S. et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J. Exp. Med. 205, 1797-1805 (2008).
52. Moir, S. & Fauci, A. S. B cells in HIV infection and disease. Nature Rev. Immunol. 9, 235-245 (2009).
53. Brooks, D. G., Lee, A. M., Elsaesser, H., McGavern, D. B. & Oldstone, M. B. IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. J. Exp. Med. 205, 533-541 (2008).
54. Brooks, D. G. et al. IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc. Natl Acad. Sci. USA 105, 20428-20433 (2008).
55. 1 T cell deletion and viral persistence in vivo. Immunity 31, 145-157 (2009).
56. Fröhlich, A. et al. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 324, 1576-1580 (2009).
57. Elsaesser, H., Sauer, K. & Brooks, D. G. IL-21 is required to control chronic viral infection. Science 324, 1569-1572 (2009).
58. Yi, J. S., Du, M. & Zajac, A. J. A vital role for interleukin-21 in the control of a chronic viral infection. Science 324, 1572-1576 (2009).
59. Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682-687 (2006).
60. Velu, V. et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458, 206-210 (2008).
61. Ha, S. J. et al. Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J. Exp. Med. 205, 543-555 (2008).
62. Araki, K. et al. mTOR regulates memory CD8 T-cell differentiation. Nature 460, 108-112 (2009).
63. Lu, W., Arraes, L. C., Ferreira, W. T. & Andrieu, J. M. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nature Med. 10, 1359-1365 (2004).
64. Lund, J. M., Hsing, L., Pham, T. T. & Rudensky, A. Y. Coordination of early protective immunity to viral infection by regulatory T cells. Science 320, 1220-1224 (2008).
65. 1 T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J. Exp. Med. 204, 595-603 (2007).
66. Gebhardt, T. et al. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nature Immunol. 10, 524-530 (2009).
67. Chachu, K. A., LoBue, A. D., Strong, D. W., Baric, R. S. & Virgin, H. W. Immune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection. PLoS Pathog. 4, e1000236 (2008).
68. Paavonen, J. et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374, 301-314 (2009).
69. 1 T lymphocytes to mucosal surfaces following intramuscular vaccination. J. Immunol. 181, 4188-4198 (2008).
70. Barton, E. S. et al. Herpesvirus latency confers symbiotic protection from bacterial infection. Nature 447, 326-329 (2007).
71. Wyand, M. S. et al. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J. Virol. 73, 8356-8363 (1999).
72. Brenchley, J. M. et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nature Med. 12, 1365-1371 (2006).
73. Slack, E. et al. Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science 325, 617-620 (2009).
74. Nix, W. A., Jiang, B., Maher, K., Strobert, E. & Oberste, M. S. Identification of enteroviruses in naturally infected captive primates. J. Clin. Microbiol. 46, 2874-2878 (2008).
75. Finkbeiner, S. R. et al. Metagenomic analysis of human diarrhea: viral detection and discovery. PLoS Pathog. 4, e1000011 (2008).
76. McKenna, P. et al. The macaque gut microbiome in health, lentiviral infection, and chronic enterocolitis. PLoS Pathog. 4, e20 (2008).
77. Ivanov, I. I. et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139, 485-498 (2009).
78. Korber, B. T., Letvin, N. L. & Haynes, B. F. T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J. Virol. 83, 8300-8314 (2009).
79. Keele, B. F. et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl Acad. Sci. USA 105, 7552-7557 (2008).
80. Vignuzzi, M., Stone, J. K., Arnold, J. J., Cameron, C. E. & Andino, R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439, 344-348 (2006).
81. Draenert, R. et al. Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus. J. Exp. Med. 203, 529-539 (2006).
82. Moore, C. B. et al. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296, 1439-1443 (2002).
83. Brumme, Z. L. et al. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One 4, e6687 (2009).
84. Miura, T. et al. HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte recognition. J. Virol. 83, 2743-2755 (2009).
85. Troyer, R. M. et al. Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog. 5, e1000365 (2009).
86. Schneidewind, A. et al. Structural and functional constraints limit options for cytotoxic T-lymphocyte escape in the immunodominant HLA-B27-restricted epitope in human immunodeficiency virus type 1 capsid. J. Virol. 82, 5594-5605 (2008).
87. Goepfert, P. A. et al. Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J. Exp. Med. 205, 1009-1017 (2008).
88. Allen, T. M. et al. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J. Virol. 78, 7069-7078 (2004).
89. Goonetilleke, N. et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 206, 1253-1272 (2009).
90. Schneidewind, A. et al. Transmission and long-term stability of compensated CD8 escape mutations. J. Virol. 83, 3993-3997 (2009).
91. Fischer, W. et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nature Med. 13, 100-106 (2007).
92. Neil, S. & Bieniasz, P. HIV, restriction factors, and interferon. J Interferon. Cytokine. Res. 29, 569-580 (2009).
93. Bushman, F. D. et al. Host cell factors in HIV replication: meta-analysis of genome-wide studies. PLoS Pathog. 5, e1000437 (2009).
94. Santiago, M. L. et al. Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science 321, 1343-1346 (2008).
95. Sheehy, A. M., Gaddis, N. C., Choi, J. D. & Malim, M. H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650 (2002).
96. Sheehy, A. M., Gaddis, N. C. & Malim, M. H. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nature Med. 9, 1404-1407 (2003).
97. Dinoso, J. B. et al. A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J. Virol. 83, 9247-9257 (2009).
98. Blazkova, J. et al. CpG methylation controls reactivation of HIV from latency. PLoS Pathog. 5, e1000554 (2009).
99. Zhang, J. X., Diehl, G. E. & Littman, D. R. Relief of preintegration inhibition and characterization of additional blocks for HIV replication in primary mouse T cells. PLoS One 3, e2035 (2008).
100. Hatziioannou, T. et al. A macaque model of HIV-1 infection. Proc. Natl Acad. Sci. USA 106, 4425-4429 (2009).
101. Tibbetts, S. A., Van Dyk, L., Speck, S. H. & Virgin, H. W. Immune control of the number and reactivation phenotype of cells latently infected with a gamma-herpesvirus. J. Virol. 76, 7125-7132 (2002).
102. Fields, B. N. AIDS: time to turn to basic science. Nature 369, 95-96 (1994).
103. Fauci, A.S.et al. HIV vaccine research: the way forward. Science 321 530-532 (2008).